EU Reviewing Zeposia as Ulcerative Colitis Treatment for Adults

EU Reviewing Zeposia as Ulcerative Colitis Treatment for Adults

281921

EU Reviewing Zeposia as Ulcerative Colitis Treatment for Adults

The anti-inflammatory medication Zeposia (ozanimod) is under review in the European Union as a treatment for adults with moderately to severely active ulcerative colitis. The European Medicines Agency has validated an application from Bristol Myers Squibb (BMS) seeking Zeposia’s approval, and will now begin its centralized review process. “This validation is an important step toward making Zeposia available to eligible patients in the European Union, who are in need of new treatment options offering proven…

You must be logged in to read/download the full post.